Interv Akut Kardiol. 2018;17(3):159-163 | DOI: 10.36290/kar.2018.020

The revival of catheter-based renal denervation?

Ján Rosa, Jan Kvasnička, Jiří Widimský jr.
III. interní klinika VFN a 1. LF UK Praha

Catheter-based renal denervation is currently not a routine method in treating arterial hypertension. The most recent studiessuggest possible effectiveness of multi-electrode systems in reducing blood pressure in the short term. However, evidence is stilllacking that the method is effective in reducing blood pressure in the long term as well as that it reduces morbidity or mortalityrates and is cost-effective given the costs associated with the procedure itself.

Keywords: renal denervation, arterial hypertension

Received: August 3, 2018; Accepted: September 11, 2018; Published: October 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rosa J, Kvasnička J, Widimský J. The revival of catheter-based renal denervation? Interv Akut Kardiol. 2018;17(3):159-163. doi: 10.36290/kar.2018.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Esler MD, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014; 35(26): 1752-1759. Go to original source... Go to PubMed...
    2. Krum H, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014; 383(9917): 622-629. Go to original source...
    3. Bhatt DL, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370(15): 1393-1401. Go to original source...
    4. Štrauch B, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis, in Journal of hypertension 2013; 2455-2461. Go to original source... Go to PubMed...
    5. Jung O, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31(4): 766-774. Go to original source...
    6. Bakris GL, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol 2015; 65(13): 1314-1321. Go to original source...
    7. Rosa J, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension 2015; 65(2): 407-413. Go to original source... Go to PubMed...
    8. Rosa J, et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. J Hypertens 2017; 35(5): 1093-1099. Go to original source...
    9. Mahfoud F, et al. Aldosterone antagonists and renal denervation: friends or foes? Hypertension 2015; 65(2): 280-282. Go to original source...
    10. Mancia G, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28): 2159-2219. Go to original source... Go to PubMed...
    11. Calhoun DA, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51(6): 1403-1419. Go to original source... Go to PubMed...
    12. Dahal K, et al. The effects of aldosterone antagonists in patients with resistant hypertension a meta-analysis of randomized and nonrandomized studies. Am J Hypertens, 2015; 28(11): 1376-1385. Go to original source...
    13. Kandzari DE, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 2015; 36(4): 219-227. Go to original source... Go to PubMed...
    14. Tzafriri AR, et al. Innervation patterns may limit response to endovascular renal denervation. J Am Coll Cardiol 2014; 64(11): 1079-1087. Go to original source...
    15. Mahfoud F, et al. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol 2015; 66(16): 1766-1775. Go to original source...
    16. Sakakura K, et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol 2014; 64(7): 635-643. Go to original source...
    17. Pekarskiy SE, et al. Denervation of the distal renal arterial branches vs. conventional main renal artery treatment: a randomized controlled trial for treatment of resistant hypertension. J Hypertens 2017; 35(2): 369-375. Go to original source...
    18. de Jong MR, et al. Renal nerve stimulation-induced blood pressure changes predict ambulatory blood pressure response after renal denervation. Hypertension 2016; 68(3): 707-714. Go to original source...
    19. de Jong MR, et al. Persistent increase in blood pressure after renal nerve stimulation in accessory renal arteries after sympathetic renal denervation. Hypertension 2016; 67(6): 1211-1217. Go to original source...
    20. Booth LC, et al. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension 2015; 65(2): 393-400. Go to original source...
    21. Pathak A, et al. Renal sympathetic nerve denervation using intraluminal ultrasound within a cooling balloon preserves the arterial wall and reduces sympathetic nerve activity. EuroIntervention 2015; 11(4): 477-484. Go to original source... Go to PubMed...
    22. Rong S, et al. Noninvasive renal denervation for resistant hypertension using high-intensity focused ultrasound. hypertension 2015; 66(4): e22-25. Go to original source... Go to PubMed...
    23. Rosa J, et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically? J Hum Hypertens, 2014; 28(11): 684-688. Go to original source... Go to PubMed...
    24. Esler M. Renal denervation for treatment of drug-resistant hypertension. Trends Cardiovasc Med 2015; 25(2): 107-115. Go to original source...
    25. Fadl Elmula FE, et al. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Press 2015; 24(5): 263-274. Go to original source... Go to PubMed...
    26. Townsend RR, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 2017; 390(10108): 2160-2170. Go to original source...
    27. Fadl Elmula FEM, et al., Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. Blood Press, 2017; 26(4): 195-203. Go to original source... Go to PubMed...
    28. Mahfoud F, et al. Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur Heart J 2017; 38(44): 3272-3281. Go to original source... Go to PubMed...
    29. Kandzari DE, et al. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J, 2016; 171(1): 82-91. Go to original source...
    30. Kandzari DE, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet, 2018; 391(10137): 2346-2355. Go to original source...
    31. Aziz, M, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet, 2018; 391(10137): 2335-2345. Go to original source...
    32. James KE, et al. An index for assessing blindness in a multi-centre clinical trial: disulfiram for alcohol cessation - a VA cooperative study. Stat Med 1996; 15(13): 1421-1434. Go to original source...
    33. Bulsei J, et al. How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example. Blood Press 2018; 27(2): 66-72. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.